Health Care · In Vitro & In Vivo Diagnostic Substances · Nasdaq · CIK 1652130 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $10.80Day −0.83%Mkt cap $1.5B1Y −13.6%Off 52W high −61.8%Vol (1Y) 98.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,566 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest32.8% of sh out |
| Days to cover9.8d |
| 13F net flow (QoQ)+6.62% |
| Top-10 13F concentration58.4% |
| Next report (est.)2026-08-10 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$66.1M |
| Earnings (TTM)-$394.6M |
| ROE−53.5% |
| Net margin−609.9% |
| Sales growth 3Y9.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+20.1% |
| 1Y−13.6% |
| 3Y−74.5% |
| 5Y−92.1% |
| 10Y−42.9% |
| Since incept. (ann.)−6.8% |
Total return through 2026-07-29 · series begins 2016-05-06. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)98.1% |
| Ann. volatility (3Y)80.3% |
| Sharpe (1Y)0.32 |
| Sharpe (3Y)−0.16 |
| Max drawdown (1Y)−71.3% |
| Max drawdown (3Y)−85.2% |
| Beta (3Y vs SPY)2.50 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| ARK Investment Management LLC | 14.5M | $186M | 10.38% | +2.1% |
| BlackRock, Inc. | 12.2M | $156M | 8.70% | +18.3% |
| STATE STREET CORP | 6.9M | $89M | 4.95% | +7.8% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.2M | $80M | 4.45% | new |
| D. E. Shaw & Co., Inc. | 5.7M | $73M | 4.10% | +7.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1M | $65M | 3.64% | new |
| TWO SIGMA INVESTMENTS, LP | 4.7M | $60M | 3.37% | +74.4% |
| REGENERON PHARMACEUTICALS, INC. | 3.7M | $47M | 2.65% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.81 | — | $15.0M | −9.5% |
| 2025-12-31 | 2026-02-26 | — | — | $23.0M | +78.8% |
| 2025-09-30 | 2025-11-06 | −$0.92 | — | $13.8M | +51.3% |
| 2025-06-30 | 2025-08-07 | −$0.98 | — | $14.2M | +104.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-10 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
